Baseline Characteristics of Dupilumab-Treated Patients with Asthma in the Real World: The RAPID Global Registry
Advances in Therapy · 2025
DOI: 10.1007/s12325-024-03051-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Therapy, 2025. Verfasst von Njira L Lugogo und 12 weiteren Autor:innen. Beteiligte Einrichtung: University of Michigan Medical School, 300 North Ingalls Street, Suite 2C40, Ann Arbor, MI, 48109, USA. nlugogo@med.umich.edu. Hauptthemen laut MEDLINE: Asthma, Antibodies, Monoclonal, Humanized, Anti-Asthmatic Agents. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sanofi, Regeneron Pharmaceuticals.
Abstract (Originalsprache)
INTRODUCTION: Patients with uncontrolled, moderate-to-severe asthma have a higher risk for exacerbations, negatively impacting lung function and quality of life. Dupilumab, a fully human monoclonal antibody, blocks interleukins 4 and 13, key and central drivers of type 2 inflammation. Dupilumab has been effective in the treatment of certain types of moderate-to-severe asthma across several clinical trials. We describe the characteristics of patients enrolled in RAPID, a global prospective registry, who initiated dupilumab (primary indication: asthma) in a real-world clinical setting. METHODS: A total of 205 patients (aged ≥ 12 years) were enrolled between March 2020 and October 2021 and are included in this analysis. Data are shown as mean (SD) unless stated otherwise. RESULTS: Patients were aged 50.1 (17.4) years and were mostly female (65.4%) and white (74.1%). At enrollment, 24.4% reported being current/former smokers and 86.8% had moderate-to-severe asthma (Global Initiative for Asthma steps 3-5). A mean (SD) of 4.4 (6.4) severe asthma exacerbations were reported in the year before enrolling in the registry in 78 of 152 patients with available data. Patients had reduced lung function [pre-bronchodilator forced expiratory volume in 1 s (FEV1): 2.3 (1.1) L; pre-bronchodilator percent predicted FEV1: 70.3 (20.3) %] and poor asthma control [6-item Asthma Control Questionnaire: 2.4 (1.2); Asthma Quality of Life Questionnaire: 4.1 (1.3)]. The median (Q1-Q3) blood eosinophil count was 305 (200-695) cells/µL and the mean (SD) fractional exhaled nitric oxide levels were 42 (35) ppb (range: 4-186 ppb). CONCLUSION: Our findings suggest that most patients who enrolled in RAPID and initiated dupilumab in real-world clinical settings had a high disease burden, despite receiving current standard-of-care treatment at enrollment. Severe asthma can be difficult to control with currently available medicines. Asthma attacks, also called asthma flare-ups or exacerbations, are episodes where symptoms such as coughing, wheezing, shortness of breath, or chest tightness can suddenly occur or worsen, severely affecting quality of life. Dupilumab is a prescription medication used, along with other medicines, to treat asthma. In clinical trials, dupilumab worked well in patients with moderate-to-severe asthma, reducing the number of asthma attacks and improving lung function, characterized by easier breathing. To determine how well dupilumab works outside of a clinical trial setting, we look at studies set in the real world (observational studies). The RAPID registry is an observational study in which adolescents and adults starting dupilumab treatment for asthma are monitored by their doctor. Here, we report information on the first 205 patients who enrolled in the RAPID study between March 2020 and October 2021. At the beginning of the study, doctors diagnosed most patients (87%) with moderate-to-severe asthma. More than half of the patients had at least one severe asthma attack in the previous year but many had more than one (average: 4.4 attacks). Overall, patients had poor lung function, asthma control, and quality of life. Many patients also showed increased levels of markers for type 2 inflammation, an immune response activating cells such as eosinophils, mast cells, and T-cells. Overall, most patients with asthma who started dupilumab in a real-world clinical setting had a high disease burden, despite receiving standard-of-care treatment at the time of enrollment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Michigan Medical School, 300 North Ingalls Street, Suite 2C40, Ann Arbor, MI, 48109, USA. nlugogo@med.umich.edu.
- Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.
- Nihon University, Tokyo, Japan.
- Quebec Heart and Lung Institute, Laval University, Quebec City, QC, Canada.
- Lillebaelt Hospital, Vejle, Denmark.
- Sanofi, Madrid, Spain.
Förderung
- Sanofi
- Regeneron Pharmaceuticals
Zitieren
APA
Lugogo, N. L., Soler, X., Gon, Y., Côté, A., Hilberg, O., Xia, C., Zhang, Y., de Prado Gómez, L., Rowe, P. J., Radwan, A., Jacob-Nara, J. A., Deniz, Y., & Peters, A. T. (2025). Baseline Characteristics of Dupilumab-Treated Patients with Asthma in the Real World: The RAPID Global Registry. Advances in Therapy. https://doi.org/10.1007/s12325-024-03051-0
Vancouver
Lugogo NL, Soler X, Gon Y, Côté A, Hilberg O, Xia C, et al. Baseline Characteristics of Dupilumab-Treated Patients with Asthma in the Real World: The RAPID Global Registry. Advances in Therapy. 2025. doi:10.1007/s12325-024-03051-0
BibTeX
@article{Lugogo2025,
author = {Lugogo, Njira L and Soler, Xavier and Gon, Yasuhiro and Côté, Andréanne and Hilberg, Ole and Xia, Changming and Zhang, Yi and de Prado Gómez, Lucía and Rowe, Paul J and Radwan, Amr and Jacob-Nara, Juby A and Deniz, Yamo and Peters, Anju T},
title = {Baseline Characteristics of Dupilumab-Treated Patients with Asthma in the Real World: The RAPID Global Registry},
journal = {Advances in Therapy},
year = {2025},
doi = {10.1007/s12325-024-03051-0}
}
EUVIMED